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Huperzine A for treatment of cognitive impairment in major 
depressive disorder: a systematic review of randomized 
controlled trials
•Systematic review and meta-analysis•
Background: Acetylcholinesterase (AChE) inhibitors have been shown to be effective in treating cognitive 
impairment in animal models and in human subjects with major depressive disorder (MDD). Huperzine A 
(HupA), a Traditional Chinese Medicine derived from a genus of clubmosses known as Huperzineserrata, is 
a powerful AChE inhibitor that has been used as an adjunctive treatment for MDD, but no meta-analysis on 
HupA augmentation for MDD has yet been reported.
Aim: Conduct a systematic review and meta-analysis of randomized controlled trials (RCTS) about HupA 
augmentation in the treatment of MDD to evaluate its efficacy and safety.  
Methods: Two evaluators independently searched nine English-language and Chinese-language databases, 
selected relevant studies that met pre-determined inclusion criteria, extracted data about outcome and 
safety, and conducted quality assessments and data synthesis.
Results: Three low-quality RCTs (pooled n=238) from China were identified that compared monotherapy 
antidepressant treatment for depression versus combined treatment with antidepressants and HupA. 
Participants in the studies ranged from 16 to 60 years of age. The average duration of adjunctive 
antidepressant and HupA treatment in the studies was only 6.7 weeks. All three studies were open label 
and non-blinded, so their overall quality was judged as poor. Meta-analysis of the pooled sample found no 
significant difference in the improvement in depressive symptoms between the two groups (weighted mean 
difference: -1.90 (95%CI: -4.23, 0.44), p=0.11). However, the adjunctive HupA group did have significantly 
greater improvement than the antidepressant only group in cognitive functioning (as assessed by the 
Wisconsin Card Sorting Test and the Wechsler Memory Scale-Revised) and in quality of life. There was no 
significant difference in the incidence of adverse drug reactions between groups.
Conclusions: The data available on the effectiveness and safety of adjunctive treatment using HupA in 
patients with MDD who are receiving antidepressants is insufficient to arrive at a definitive conclusion 
about its efficacy and safety. Pooling of the data from three low-quality RCTs from China found no advantage 
of adjunctive HupA in the treatment of depressive symptoms, but adjunctive treatment with HupA was 
associated with a faster resolution of the cognitive symptoms that frequently accompany MDD.
Trial registration number: CRD42015024796 (http://www.crd.york.ac.uk/prospero/)
Key words: depression; meta-analysis; cognitive function; huperzine A; adjunctive treatment
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1. Introduction
Major depressive disorder (MDD) is a common 
psychiatric illness that is often associated with cognitive 
dysfunction.[1] One hypothesis about the mechanism 
of cognitive decline in MDD links it to decreasing 
acetylcholinesterase (AChE) activity of the cholinergic 
system in the hippocampus, frontal cortex, and 
septum.[2] Some studies suggest that AChE inhibitors 
(e.g., donepezil,[3] rivastigmine,[4] and galantamine[5]) 
can ameliorate cognitive impairment in animal models 
of depression and in humans with MDD.[5-7] Huperzine 
A (HupA) is a Traditional Chinese Medicine (TCM) 
isolated from Huperzineserrata (a genus of clubmosses), 
also known as ground pines or creeping cedar, in the 
family Lycopeodiaceae (a family of fern-allies). It is a 
powerful, highly specific, and reversible inhibitor of 
AChE.[8-10] Because of its popularity as a TCM medication 
in mainland China, extensive clinical experience and 
research about HupA in China may help clarify the 
mechanism of action for its potential efficacy in the 
treatment of MDD. However, to date no systematic 
review or meta-analysis on HupA augmentation for 
MDD has been published. The primary aim of this study 
was to conduct a systematic review and meta-analysis 
about the efficacy and safety of HupA in the treatment 
of MDD based on published RCTs identified by searching 
international and Chinese databases.
2. Methods 
2.1 Types of studies
All publications of randomized controlled trials (RCTs) 
which reported on the efficacy and/or safety of 
antidepressants combined with HupA in the treatment 
of MDD were eligible for inclusion. Case reports/series, 
observational trials, meta-analyses, and systematic 
reviews were excluded.
2.2 Outcome measures
The primary outcome measure of interest was 
cognitive function measured by the Wisconsin Card 
Sorting Test (WCST)[11] or the Wechsler Memory Scale-
Revised, Chinese version (WMS-RC).[12] Key secondary 
outcomes were improvement in depressive and anxiety 
symptoms assessed by the Hamilton Depression 
Rating Scale (HAMD)[13] and the Hamilton Anxiety 
Rating Scale (HAMA),[14] self-reported quality of life 
assessed by the General Quality of Life Inventory of the 
World Health Organization (WHOQOL-100),[15] causes 
for discontinuation of treatment, and adverse drug 
reactions measured by the Dosage Record Treatment 
Emergent Symptom Scale (DOTES).[16] Clinical outcomes 
were based on intent-to-treat (ITT) analysis.
2.3 Selection of studies 
PubMed, PsycINFO, Embase, Cochrane Library 
databases, the Cochrane Controlled Trials Register, 
ClinicalTrials.gov (https://www.clinicaltrials.gov/), 
and Chinese databases (WanFang Database, Chinese 
Biomedical database, and China Journal Net) were 
searched from the inception of the databases through 
March 12, 2016 using the following search terms: 
(Depressive Disorders OR Disorder, Depressive OR 
Disorders, Depressive OR Neurosis, Depressive OR 
Depressive Neuroses OR Depressive Neurosis OR 
Neuroses, Depressive OR Depression, Endogenous OR 
Depressions, Endogenous OR Endogenous Depression 
OR Endogenous Depressions OR Depressive Syndrome 
OR Depressive Syndromes OR Syndrome, Depressive 
OR Syndromes, Depressive OR Depression, Neurotic 
OR Depressions, Neurotic OR Neurotic Depression OR 
Neurotic Depressions OR Melancholia OR Melancholias 
OR Unipolar Depression OR Depression, Unipolar OR 
Depressions, Unipolar OR Unipolar Depressions) AND 
(Huperzine A OR Huperzine OR HupA) AND (randomized 
controlled trial OR controlled clinical trial OR randomized 
OR placebo OR drug therapy OR randomly OR trial OR 
groups). We also hand-searched reference lists from 
identified and relevant review articles for additional 
studies and contacted authors for unpublished data.
2.4 Data extraction
Two authors (ZW and XYQ) independently conducted 
the literature search and extracted the data. Any 
disagreement was resolved by a third author (XYT). Data 
presented only in graphs and figures were extracted 
whenever possible. Authors were contacted to obtain 
missing information or clarification if possible. If cases 
were from multicenter studies, whenever possible, data 
were extracted separately for each center.
2.5 Statistical methods
We used RevMan (version 5.1.7.0) in this meta-analysis 
according to the recommendations of the Cochrane 
Collaboration. For continuous data, weighted mean 
difference (WMD) with 95% CI was used to compare 
groups, and for dichotomous data, risk ratio (RR) 
with 95% confidence intervals (Cis) were computed 
to compare groups. The I2 statistic assessed statistical 
heterogeneity between the three studies: when I2≥50%, 
a random effects model was used;[17] otherwise, a fixed 
effect model was employed.[18] All analyses were two- 
tailed with alpha set at 0.05.
2.6 Risk of bias assessment
The methods of random sequence generation (selection 
bias), allocation concealment (selection bias), blinding of 
participants and personnel (performance bias), blinding 
of outcome assessment (detection bias), incomplete 
outcome data (attrition bias), selective reporting 
(reporting bias), and other biases were assessed using 
the Risk of Bias (ROB) scale developed to assess RCTs by 
the Cochrane Collaboration.[19]
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3. Results
3.1 Results of the literature search
The search yielded 54 potentially relevant articles, of 
which four articles were published in English and 50 
in Chinese. Of the 54 studies, 3 RCTs met the inclusion 
criteria.[20-22] As shown in Figure 1, the total number of 
subjects included in the three studies was 238, with 119 
receiving an antidepressant augmentated with HupA 
and 119 only receiving an antidepressant.
3.2 The characteristics of included studies
As shown in  Table 1,  a l l  three RCTs [20-22]were 
conducted in China and used the criteria of the 
Chinese Classification of Mental Disorders, 3rd edition 
(CCMD-3)[23] to diagnose depression. Males accounted 
for 45.4% of the sample (range 30% to 58% in the 
three studies), the weighted mean age of participants 
was 29.6 (range 16-60) years; and the weighted mean 
duration of illness was 3.3 (range 1.2 to 5.2) years. The 
weighted mean duration of the treatment trial reported 
in the studies was 6.7 (range 6-8) weeks. None of the 
studies were supported by pharmaceutical companies.
3.3 Assessment of risk of bias 
The risk of different types of biases of the three studies 
is shown in Table 2. Two studies [21-22] mentioned 
“random” assignment without a description of the 
method of randomizing, and one RCT[20] was rated 
as high risk of selection bias because patients were 
                                                                                                                                                                                                                                                    
                                            
                                                         
                                       
54 articles published before May 12, 2016 were identified using a standard search strategy and other sources 
(see methods section):
• 24   from China Journal Net
• 14   from WanFang Database
• 12   from Chinese Biomedical database
•   2   from Embase
•   1   from PubMed
•   1   from Cochrane Library databases
•   0   from PsycINFO
•   0   from Cochrane Controlled Trials Register 
•   0   from ClinicalTrials.gov (https://www.clinicaltrials.gov/)
6 duplicates removed
Figure 1. Identification of included studies
48 unduplicated studies; 44 published in Chinese, 4 in English
40 articles excluded based on title and abstract
8 full-text articles assessed for eligibility
5 full-text articles excluded:
• 3  had no major depressive disorder diagnosis
• 1  review
• 1  animal study
3 studies included in qualitative synthesis and in meta-analysis
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classified into two groups according to the order of 
admission. None of the studies were blinded so the 
risk of allocation bias, performance bias, and detection 
bias were high. The studies reported the outcomes of 
all enrolled subjects, so the risk of attrition bias was 
low; but in the absence of study registration materials it 
was impossible to determine whether or not there was 
selective reporting (i.e., reporting bias). There was no 
evidence of other types of biases (e.g., drug company 
sponsorship of the study). Overall, all three studies were 
considered at high risk of bias and, thus, relatively low-
quality studies. 
Because there were only three RCTs included in the 
meta-analysis, publication bias could not be tested.[24]
3.4 Changes in severity of depressive symptoms
In all three studies there were differences between 
groups in changes of the total HAMD score over 
Table 1. Characteristics of included studies
Study N
Design
Setting
Trial 
duration
(weeks)
Country
Diagnosis
Diagnostic 
criteria
Mean 
illness 
duration
Weighted 
mean age 
in years 
(range)
Male
n 
(%)
Interventions: 
[M] mean dose (mg/day)
[R] range (mg/day)
[n] number of patients
Outcome 
assessments
Gao 
2007[20] 100
Open-label
Inpatients 
and 
outpatients
6 China
MDD
CCMD-3
5.2 years
30.4 
(18-50)
30
(30%)
1. FLU(M=NR; R=20-40) + HupA
    (fixed dose at 0.3); n=50
2. FLU(M=NR; R=20-40); n=50
HAMD; 
WCST; 
WHOQOL-100
Yang 
2010[21] 78
Open-label
Inpatients 
and 
outpatients
8 China
MDD
CCMD-3
2.5 years
29.9 
(18-60)
45
(58%)
1. FLU(M=NR; R=20-40) + HupA
     (fixed dose at 0.3); n=39
2. FLU(M=NR; R=20-40); n=39
HAMD; 
WMS-RC
Liu 
2010[22] 60
Open-label
Inpatients 
and 
outpatients
6 China
MDD
CCMD-3
1.2 years
27.9 
(16-48)
33
(55%)
1. VEN(M=107; R=50-150) + HupA     
    (M=NR; R=0.1-0.2); n=30
2. VEN(M=105; R=50-150); n=30
HAMD; 
HAMA;
DOTES
MDD, Major Depressive Disorder
CCMD-3, Chinese Mental Disorders Classification and Diagnostic 
Criteria, Third Edition[23]
FLU, fluoxetine
NR, not recorded
HupA, huperzine A
HAMD, Hamilton Depression Rating Scale[13]
WCST, Wisconsin Card Sorting Test[11]
WHOQOL-100, General Quality of Life Inventory of World Health 
                            Organization[15]
WMS-RC, Wechsler Memory Scale-Revised, Chinese version[12]
VEN, venlafaxine 
HAMA, Hamilton Anxiety Rating Scale[14]
DOTES, Dosage Record Treatment Emergent Symptom Scale[16]
Table 2. Evaluation of risk of bias in the three included studies
study sequence generation
allocation 
sequence 
concealment
blinding of 
participants and 
personnel
blinding of 
outcome 
assessment
incomplete 
outcome 
data
selective 
outcome 
reporting
other potential 
threats 
to validity
Gao 
2007[20] high high high high low N/A low
Yang 
2010[21] N/A high high high low N/A low
Liu 
2010[22] N/A high high high low N/A low
N/A=no information available
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the study period. As shown in Figure 2, one of the 
studies[22] reported a significantly greater reduction 
of depressive symptoms (based on the HAMD) when 
adjunctive HupA was provided to patients with MDD 
being treated with antidepressants, but the other two 
studies did not find a significant advantage of adjunctive 
treatment with HupA. When pooling the three studies 
in a random effects meta-analysis, there was no 
statistically significant difference in the improvement 
in depressive symptoms between MDD patients who 
only received antidepressants and those who received 
antidepressants and adjunctive HupA.
3.5 Cognitive results
The other results from the three studies are shown in 
Table 3. Only two studies[20,21] assessed the cognitive 
effects of the treatment. Both studies reported a 
significant advantage of using adjunctive HupA. In one 
study,[21] memory functioning at the end of the 8-week 
trial was better in patients taking antidepressants 
with adjunctive HupA than in those who were only 
taking antidepressants. In another study,[20] several 
measures of executive functioning derived from the 
WCST were significantly better at the end of the 6-week 
trial in depressed patients taking antidepressants with 
adjunctive HupA. These cognitive outcome measures 
were quite different so it was not possible to pool the 
results of the two studies into a meta-analysis. 
3.6 Other results
The level of anxiety was only assessed in one of the 
studies.[22] Based on the total score of the HAMA at 
the end of the 6-week trial, there was no significant 
difference in the severity of anxiety symptoms between 
the two groups (Table 3). 
Only one study[20] assessed quality of life. As 
measured by WHOQOL-100,[15] quality of life was 
significantly better at the end of the trial in individuals 
who received combined treatment with antidepressants 
and HupA (Table 3).
Only one study [22] assessed adverse reactions. The 
study assessed adverse events using the DOTES[16] which 
considers tachycardia, dysuria, electrocardiographic 
abnormality,  dry mouth,  drowsiness,  nausea, 
constipation, blurred vision, and insomnia. It found no 
difference in the prevalence of adverse events between 
the two treatment groups 
None of the included RCTs reported the rate or 
causes of treatment discontinuation.
4. Discussion
4.1 Main finding
Despite an extensive review of both English-language 
and Chinese-language literature, we only identified three 
RCTs that assessed the potential benefit of adjunctive 
HupA when treating individuals with depression who 
are currently using antidepressants. All three studies 
were open label and the outcome evaluation in the 
trials was not blinded, so the overall strength of the 
studies was rated as ‘poor’. The pooled sample from the 
three studies, all of which were published in Chinese, 
was 238 individuals, but it was only possible to conduct 
a meta-analysis for the results related to changes in 
depressive symptoms because other outcomes of 
interest (e.g., cognitive changes, quality of life changes, 
etc.) were only considered in one or two of the studies. 
Overall, the results suggest that adjunctive treatment 
with HupA over 6 to 8 weeks in patients with depression 
who are currently taking antidepressants does not 
Figure 2. Adjunctive Huperzine A for MDD: forest plot for improvement in depressive symptoms assessed by 
change in total score of the Hamilton Depression Scale
Study
Random eﬀects model
Heterogeneity: I2=57.5%, tau2=2.444, p=0.0948
Test for overall eﬀect: Z=1.59 p=0.1111
Gao 2007[20]
Liu 2010[22]
Yang 2010[21]
Total
119
 50
 39
 30
Mean
12.06
 6.11
 8.10
SD
6.52
3.47
6.30
Experimental
Total
119
 50
 39
 30
Mean
13.04
 9.98
 8.30
SD
7.30
5.77
6.20
Control
−20 −15 −10 −5 0 5
Mean diﬀerence
MD
−1.90
−0.98
−3.87
−0.20
95%CI
[−4.23;  0.44]
[−3.69;  1.73]
[−5.98; −1.76]
[−3.36;  2.96]
Weight (random)
100%
32.5%
39.3%
28.1%
favors experimental favors control
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Table 3. Comparison of cognitive function, anxiety, and quality of life in patients with depression at end of 
course of treatment with either antidepressants and adjunctive HupA (experimental group) or with 
antidepressants alone (control group)
measure study
control group experimental group
t-test (p)
n mean (sd) n mean (sd)
Cognitive measures
  WMS-RC Yang[21] 39 92.1 (16.7) 39 103.0 (15.0) 3.04 (0.003)
  WCST (non-perseverative errors) Gao[20] 50 35.7 (5.4) 50 27.5 (8.5) 5.71 (<0.001)
  WCST (perseverative errors) Gao[20] 50 37.7 (7.4) 50 26.4 (9.7) 6.60 (<0.001)
  WCST (correct responses) Gao[20] 50 24.3 (6.2) 50 31.9 (11.3) 4.17 (<0.001)
  WCST (categories completed) Gao[20] 50 3.96 (0.83) 50 4.52 (1.07) 2.92 (0.004)
Anxiety (HAMA total score) Liu[22] 30 8.1 (7.3) 30 8.3 (7.3) 0.11 (0.909)
WHOQOL-100 total score Gao[20] 50 12.9 (3.9) 50 18.6 (12.5) 3.08 (0.003)
WMS-RC, Wechsler Memory Scale-Revised, Chinese version[12]
WCST, Wisconsin Card Sorting Test[11]
HAMA, Hamilton Anxiety Rating Scale[14]
WHOQOL-100, General Quality of Life Inventory of World Health Organization[15]
result in a better reduction of depressive symptoms, 
but it does appear to lead to less cognitive impairment 
in depressed individuals and, possibly, to a better self-
reported quality of life for depressed individuals.
4.2 Limitations
The small number of studies identified and the limited 
measures employed in the identified studies made it 
impossible to conduct a full meta-analysis, so we could 
not do a sensitivity analysis or subgroup analyses, and 
we could not construct a funnel plot to assess potential 
publication bias. Specifically, there were not enough 
studies with data on cognitive functioning to conduct a 
meta-analysis of this important outcome. Moreover, the 
relatively low quality of the available studies (open label, 
non-blinded) and the relatively short duration of the 
studies (from 6 to 8 weeks) means that the findings that 
were significant – the benefit of HupA augmentation 
for cognitive functioning and quality of life in depressed 
patients – are not robust; they need to be replicated in 
larger, methodologically more rigorous RCTs that follow 
participants for much longer.
4.3 Importance
Despite the limited number of RCTs identified and 
the methodological limitations of the identified 
studies,[25] this review does provide some support for 
the suggestion that AChE inhibitors such as HupA can 
ameliorate the cognitive decline that is often associated 
with depression and, possibly, improve the quality of 
life of individuals being treated for depression with 
antidepressant medications. Similar to our findings, a 
recent meta-analyses[26] found that adjunctive HupA 
is an effective choice for improving cognitive function 
in individuals with schizophrenia. The mechanism of 
action of HupA in improving cognitive functioning (or 
preventing cognitive decline) remains unknown, but 
given the importance of cognitive impairment in a wide 
range of mental disorders, further work in this promising 
area is merited. 
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背景：乙酰胆碱酯酶 (Acetylcholinesterase, AChE) 抑制
剂在重性抑郁障碍 (Major Depressive Disorder, MDD) 的
动物模型和人类患者中已被证实可以有效地治疗认知
障碍。石杉碱甲 (Huperzine A, HupA) 是一种来自于被称
为蛇足石杉 (Huperzineserrata) 的石松属传统中医药，
是一种强有力的 AChE 抑制剂，已被用于抑郁症的辅助
治疗，但有尚无关石杉碱甲对 MDD 的强化治疗作用的
meta 分析。
目标：对有关石杉碱甲强化治疗抑郁症的随机对照试
验进行系统综述和 meta 分析，评估其疗效及安全性。
方法：两位评估者独立检索 9 个英文和中文数据库，
选择符合预先确定的纳入标准的相关研究，提取有关
疗效和安全性的数据，并进行质量评估和数据拟合合
成。
结果：纳入了三项中国低质量的随机对照试验（总共
n=238），这些试验比较了单用抗抑郁药治疗抑郁症与
抗抑郁药和石杉碱甲的联合治疗，试验中的被试从 16
岁到 60 岁。研究中石杉碱甲辅助抗抑郁药治疗的平均
时间仅为 6.7 周。这三项研究都是公开标签未使用盲
法，所以他们的总体质量评定为差。总体样本的 Meta
分析发现两组抑郁症状的改善没有显著性差异（差
异加权差为 -1.90，95%CI 可信区间为 -4.23 至 0.44，
p=0.11）。然而，石杉碱甲辅助治疗组比单用抗抑郁
药治疗组在认知功能和生活质量方面有显著改善（如
威斯康星卡片分类测验、韦氏记忆量表修订的评估）。
组间药物不良反应的发生率无显著性差异。
结论：有关在接受抗抑郁药的 MDD 患者使用 HupA 辅
助治疗的疗效和安全性的可获取数据不足，难以得出
有关其疗效和安全性的明确结论。汇集国内 3 项低质
量的 RCT 数据没有发现采用辅助使用 HupA 治疗抑郁
症状的优势，但辅助使用 HupA 与更快改善经常伴随
MDD 出现的认知症状相关。
试验注册号码：CRD42015024796 (http://www.crd.york.
ac.uk/prospero/)
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